Trial Profile
A Multicenter, Randomized, Double-blind, Phase 3 Study to Evaluate Efficacy and Safety of HM11260C in Adult Obesity Patients Without Diabetes Mellitus
Status:
Not yet recruiting
Phase of Trial:
Phase III
Latest Information Update: 20 Dec 2023
Price :
$35
*
At a glance
- Drugs Efpeglenatide (Primary)
- Indications Obesity
- Focus Therapeutic Use
- Sponsors Hanmi Pharmaceutical
- 08 Dec 2023 Status changed from planning to not yet recruiting.
- 18 Dec 2017 New trial record
- 13 Dec 2017 According to a Sanofi media release, the company expects to initiate this study in 2018.